San Francisco, 15 January, Cervical
Cancer Diagnostic Market Analysis By Test Type (Pap Testing Or Cytology
Testing, HPV Testing, Colposcopy, Cervical Biopsies, Cystoscopy) And Segment
Forecasts To 2024 .
The global cervical cancer diagnostic market was valued at USD 7
billion in 2015 and is expected to reach a value of USD 12 billion by 2024,
according to a new report by Grand View Research, Inc. The key driving factors
include the rising prevalence of cervical cancer, evolving screening
technology, and various programs that promote routine check up and screening.
According to the data published by the WHO, in 2012, over 270,000 women died
due to cervical cancer, majority of which were from the developing countries.
It is one of the most common cancer type diagnosed in women. Some of the
etiological factors are multiple sex partners, and changing lifestyle, such as
drinking & smoking and increased stress levels.
Furthermore, favorable
government initiatives and increasing number of awareness programs are further
expected to promote the market growth in coming few years. The National
Cervical Cancer Coalition, WHO, CDC, the U.S. Preventive Services Task Force,
are working towards promoting the necessity for early screening of cervical
cancer amongst mid aged women.
There is an increasing demand
for technologically advanced diagnostic procedures that facilitate the early
intervention of the disease. The industry players are focused on developing
innovative technological solutions for accurate and efficient results.
Advancement in screening techniques, such as use of biomarkers, is gaining
importance. The upsurge in technological developments is anticipated to further
drive industry growth.
On account of increasing
adoption of Pap test, the number of deaths due to cervical cancer has declined
significantly in past few years. It helps detect precancerous lesions at an
early state and, thus, reduces the number of cervical cancer cases. The
American Cancer Society stated that the cervical cancer cases in last 40 years
in the U.S. have declined by more than 50%. Initially, the Pap test screening
was carried out every year which lead to further unnecessary procedures. However,
the American Cancer Society now recommends that women in the age group of 21 to
29 should undergo Pap test every 3 years.
Access Full Research
Report On Cervical Cancer Diagnostic Market Analysis:
Further Key Findings from the Study Suggest:
·
In 2015, the Pap testing
segment held majority of the market share of 49.6%. The segment’s large share
can be attributed to the high efficiency of the tests in early diagnosis. Also,
the increasing awareness about the impact of early diagnosis contributed to its
growth.
·
In 2015, North America was the
leading regional market with a revenue share of 48.3%. The U.S. is a key market
in North America. Growing incidence of cervical cancer coupled with initiatives
undertaken by government agencies in the form of awareness programs pertaining
to the early screening of the disease are key factors for the country’s large
market share.
·
Asia Pacific is expected to
witness lucrative growth over the forecast period growing at a CAGR of 9.6%.
The various steps undertaken by governments of developing countries such as
India, China, Philippines, and other in order to improve healthcare
infrastructure and to improve access to healthcare facilities are amongst key
factors attributing to region’s high growth. Also, high prevalence of cancer in
developing nations and increasing consumer awareness levels drive the growth
·
This market is presently
dominated by a few key participants such as Becton, Dickinson and Company, F.
Hoffmann-La Roche Ltd, Abbott Laboratories, OncoHealth Corp, Hologic, Inc.,
QIAGEN, Quest Diagnostics, Inc and Guided Therapeutics, Inc. The key players
focus specially on developing innovative solutions for diagnosis. For instance,
F. Hoffmann-La Roche Ltd., in 2014, launched automated CINtec PLUS cytology
test that efficiently detects the presence of precancerous cells.
Browse More Reports Of This Category By
Grand View Research At: www.grandviewresearch.com/industry/clinical-diagnostics
Grand View Research has segmented the
Cervical cancer diagnostic market by outsourcing services, application, end
use, and region:
Test type outlook (Market
revenue in USD Billion, 2013 - 2024)
·
Pap Testing
·
HPV Testing
·
Colposcopy
·
Cervical Biopsies
·
Cystoscopy
Regional outlook (Market
revenue in USD Billion, 2013 - 2024)
·
North America
o
U.S.
o
Canada
·
Europe
o
UK
o
Germany
·
Asia Pacific
o
Japan
o
China
·
Latin America
o
Brazil
o
Mexico
·
Middle East and Africa
o
South Africa
Access Full Press Release of this Report:
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and
consulting company, registered in the State of California and headquartered in
San Francisco. The company provides syndicated research reports, customized
research reports, and consulting services. To help clients make informed
business decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
For more information: www.grandviewresearch.com/
No comments:
Post a Comment